TABLE 6.
Characteristics of individual sulfonylurea drug users
| Glimepiride | Glibenclamide | Gliclazide | Tolbutamide | P‐value | |
|---|---|---|---|---|---|
| N | 222 | 41 | 117 | 148 | |
| Age, years, mean (SD) | 72.0 (9.6) | 73.6 (9.5) | 73.8 (9.5) | 75.0 (10.0) | .034 |
| Male, n (%) | 167 (75.2) | 33 (80.5) | 97 (82.9) | 122 (82.4) | .251 |
| Concomitant drug use, n (%) | |||||
| Beta blockers | 95 (42.8) | 14 (34.1) | 53 (45.3) | 58 (39.2) | .556 |
| Calcium channel blockers | 50 (22.5) | 11 (26.8) | 32 (27.4) | 28 (18.9) | .389 |
| Antithrombotics | 89 (40.1) | 21 (51.2) | 54 (46.2) | 61 (41.2) | .469 |
| Diuretics | 114 (51.4) | 21 (51.2) | 57 (48.7) | 62 (41.9) | .334 |
| Renin‐angiotensin system inhibitors | 144 (64.9) | 25 (61.0) | 80 (68.4) | 87 (58.8) | .405 |
| Nitrates | 34 (15.3) | 5 (12.2) | 16 (13.7) | 25 (16.9) | .842 |
| Statins | 140 (63.1) | 17 (41.5) | 72 (61.5) | 89 (60.1) | .077 |
| Vaughan‐Williams class 1 or 3 antiarrhythmic drugs | 10 (4.5) | 1 (2.4) | 2 (1.7) | 3 (2.0) | .409 |
| Non‐cardiac QT‐prolonging drugs | 10 (4.5) | 1 (2.4) | 4 (3.4) | 7 (4.7) | .885 |
Numbers are number (%) unless indicated otherwise. P‐values are calculated using ANOVA or χ2 statistics.
Use of individual sulfonylurea drugs was defined as use within 90 days before the index date. Use of beta blockers, calcium channel blockers, antithrombotics, diuretics, renin‐angiotensin system inhibitors, nitrates and/or statins was defined as use within 6 months before the index date. Use of Vaughan‐Williams class 1 or 3 antiarrhythmic drugs and/or non‐cardiac QT‐prolonging drugs was defined as use within 90 days before the index date.